Abstract: The National Cancer Institute’s Cancer Moonshot Biobank has surpassed 1,000 participant enrollments, marking a major step forward in building a national resource for cancer research. With over 1,300 participants enrolled across 77 sites, the initiative is focused on collecting longitudinal biospecimens to better understand treatment response and drug resistance.
Unlike traditional biobanks, this initiative collects blood and tumor samples at multiple stages of a patient’s treatment journey. This longitudinal approach enables researchers to track how tumors evolve and why certain therapies lose effectiveness.
Launched in 2020, the biobank supports patients undergoing targeted therapies, treatments designed to act on specific genetic mutations. These samples are analyzed to generate biomarker insights, which may also assist clinicians in making informed treatment decisions.
Another key strength of the initiative is its diverse cohort, including participants from underrepresented and rural populations. This ensures that research outcomes are more inclusive and applicable across different demographics.
As enrollment nears completion in 2026, the biobank is set to become a valuable national resource, enabling researchers to explore tumor progression, improve reproducibility, and accelerate advancements in precision oncology.
Get the full article here: https://www.biobanking.com/nci-cancer-moonshot-biobank-surpasses-1000-enrollment-milestone/
